“The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study” (2020) SKIN The Journal of Cutaneous Medicine, 4(6), p. s93. doi:10.25251/skin.4.supp.93.